Treatment with IL-13Rα2/TGF-β CAR-T cells in human and mouse GBM models has demonstrated increased T cell infiltration, reduced levels of suppressive myeloid cells in the tumor-bearing brain, and improved survival rates in patient-derived GBM xenografts and syngeneic mouse models. The gene discussed is IL13RA2; the disease is neoplasm.